SPY768.06+0.16%QQQ694.05+0.30%BTC/USD80,518.67+4.11%DIA533.85+0.14%GLD372.10−0.10%TLT81.72−0.05%

Premium Services

PAVmed Inc

PAVMNASDAQ

Trade with Public

Trade with Public

$1.66

-0.16-8.79%

Last update: Nov 4, 9:23 AM

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Stock Report

Connect With Us

About Benzinga

Market Resources

Advanced Stock Screener Tools
Options Trading Chain Analysis
Comprehensive Earnings Calendar
Dividend Investor Calendar and Alerts
Economic Calendar and Market Events
IPO Calendar and New Listings
Market Outlook and Analysis
Wall Street Analyst Ratings and Targets

Trading Tools & Education

Ring the Bell

© 2026 Benzinga | All Rights Reserved

PAVmed (PAVM) Stock Price Target 2026

The average analyst price target for PAVmed is $57, 2900.0% above the current price. The one analyst covering it rates it Buy. The latest change came on Aug 27, 2026, when Ascendiant Capital raised its price target on PAVmed from $56 to $57 and kept a Buy rating.

The Average Analyst Price Target for PAVmed is $57.

Price Target Range — 6 Quarters

Analyst Consensus — 1 Analysts

1Buy

Consensus RatingBuy# Analysts1Avg. Consensus PT$57Upside to Avg. PT+2900.0%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for PAVmed Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 27, 2026	Ascendiant Capital	Edward Woo	PT Raise	Buy	$56→$57
Jun 8, 2026	Ascendiant Capital	Edward Woo	PT Cut	Buy	$65→$56
Apr 9, 2026	Ascendiant Capital	Edward Woo	PT Cut	Buy	$510→$65
Dec 10, 2025	Ascendiant Capital	Edward Woo	PT Cut	Buy	$600→$510
Oct 6, 2025	Ascendiant Capital	Edward Woo	PT Raise	Buy	$570→$600
Jun 6, 2025	Ascendiant Capital	Edward Woo	PT Cut	Buy	$585→$570
Apr 21, 2025	Ascendiant Capital	Edward Woo	PT Raise	Buy	$570→$585
Dec 9, 2024	Ascendiant Capital	Edward Woo	PT Cut	Buy	$630→$570
Sep 10, 2024	Ascendiant Capital	Edward Woo	PT Cut	Buy	$660→$630

Analyst Ratings News

Nvidia To Rally Around 146%? Here Are 10 Top Analyst Forecasts For Thursday

Wall Street analysts changed outlook on top names: Evercore raised Salesforce target, Needham raised Nutanix target, Ascendiant raised PAVmed target, Cantor raised Okta target, Piper raised Veeva target, Cantor boosted Solid Biosciences target, BTIG raised Crowdstrike target, Cantor cut Dycom target.

Avi Kapoor

PRO
Ascendiant Capital Maintains Buy on PAVmed, Raises Price Target to $57

Ascendiant Capital analyst Edward Woo maintains PAVmed (NASDAQ:PAVM) with a Buy and raises the price target from $56 to $57.

Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on PAVmed, Lowers Price Target to $56

Ascendiant Capital analyst Edward Woo maintains PAVmed (NASDAQ:PAVM) with a Buy and lowers the price target from $65 to $56.

Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on PAVmed, Lowers Price Target to $17

Ascendiant Capital analyst Edward Woo maintains PAVmed (NASDAQ:PAVM) with a Buy and lowers the price target from $20 to $17.

Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on PAVmed, Raises Price Target to $20

Ascendiant Capital analyst Edward Woo maintains PAVmed (NASDAQ:PAVM) with a Buy and raises the price target from $19 to $20.

Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on PAVmed, Lowers Price Target to $19

Ascendiant Capital analyst Edward Woo maintains PAVmed (NASDAQ:PAVM) with a Buy and lowers the price target from $19.5 to $19.

Benzinga Newsdesk